PSYCHOLOGICAL AND BEHAVIORAL REACTIONS WHEN PATIENTS WITH RHEUMATOID ARTHRITIS START BIOLOGICAL DMARDS

被引：0
|
作者：
Motonaga, T. [1 ]
Mori, M. [2 ]
Mabuchi, M. [3 ]
Sakai, Y. [4 ]
Iijima, Y. [5 ]
Hidaka, T. [6 ]
Kameda, H. [7 ]
Kawahito, Y. [8 ]
机构：
[1] Teikyo Univ, Tokyo, Japan
[2] Jikei Univ, Sch Med, Tokyo, Japan
[3] Tokyo Univ Agr & Technol, Tokyo, Japan
[4] Atomi Univ, Tokyo, Japan
[5] Nippon Koukan Hosp, Kawasaki, Kanagawa, Japan
[6] Zenjinkai Shimin No Mori Hosp, Miyazaki, Japan
[7] Toho Univ, Tokyo, Japan
[8] Kyoto Prefectural Univ Med, Kyoto, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.5323
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1226
引用
收藏
页码：1344 / 1345
页数：2
相关论文
共 50 条
  • [21] Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis
    Tanaka, Yoshiya
    Hirata, Shintaro
    DRUGS, 2014, 74 (18) : 2129 - 2139
  • [22] SURVIVAL ANALYSIS OF BIOLOGICAL DMARDS AND JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS REQUIRING SWITCHING OF TREATMENT
    Bobkova, A. O.
    Glukhova, S. I.
    Karateev, A. E.
    Potapova, A. S.
    Lila, A. M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S149 - S150
  • [23] COMPARISON OF TOFACITINIB SAFETY AND EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS, OR TO ONE OR MORE BIOLOGICAL DMARDS
    Charles-Schoeman, C.
    Kremer, J.
    Krishnaswami, S.
    Soma, K.
    Geier, J.
    Zhang, R.
    Strengholt, S.
    Burmester, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 271 - 272
  • [24] Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
    Genovese, Mark
    Combe, Bernard
    Hall, Stephen
    Rubbert-Roth, Andrea
    Zhong, Sheng
    Meerwein, Sebastian
    Pangan, Aileen
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [25] Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
    Terslev, Lene
    Brahe, Cecilie Heegaard
    Hetland, Merete Lund
    Georgiadis, Stylianos
    Ellegaard, Karen
    Juul, Lars
    Tuan Huynh
    Dohn, Uffe Moller
    Fana, Viktoria
    Moller, Torsten
    Krabbe, Simon
    Ornbjerg, Lykke Midtboll
    Glinatsi, Daniel
    Rogind, Henrik
    Hansen, Anette
    Norregaard, Jesper
    Jacobsen, Soren
    Jensen, Dorte Vendelbo
    Manilo, Natalia
    Asmussen, Karsten
    Boesen, Mikael
    Rastiemadabadi, Zoreh
    Morsel-Carlsen, Lone
    Moller, Jakob Mollenbach
    Krogh, Niels Steen
    Ostergaard, Mikkel
    RHEUMATOLOGY, 2021, 60 (12) : 5549 - 5559
  • [26] Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
    Terslev, L.
    Ostergaard, Mikkel
    Georgiadis, Stylianos
    Brahe, Cecilie Heegaard
    Ellegaard, Karen
    Dohn, Um
    Fana, Viktoria
    Moller, Torsten
    Juul, Lars
    Tuan Khai Huynh
    Krabbe, Simon
    Ornbjerg, L. M.
    Glinatsi, Daniel
    Rogind, Henrik
    Hansen, Annette
    Norregaard, Jesper
    Jacobsen, Soren
    Jensen, Dorte, V
    Manilo, Natalia
    Asmussen, Karsten
    Boesen, Mikael
    Rastiemadabadi, Zoreh
    Morsel-Carlsen, Lone
    Moller, Jakob Mollenbach
    Krogh, Niels Steen
    Hetland, Merete Lund
    RMD OPEN, 2022, 8 (02):
  • [27] Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis
    Yoshiya Tanaka
    Shintaro Hirata
    Drugs, 2014, 74 : 2129 - 2139
  • [28] Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis
    Wolfe, F
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1997, 15 (03) : S75 - S81
  • [29] Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis
    Orsolini, Giovanni
    Fassio, Angelo
    Rossini, Maurizio
    Adami, Giovanni
    Giollo, Alessandro
    Caimmi, Cristian
    Idolazzi, Luca
    Viapiana, Ombretta
    Gatti, Davide
    PHARMACOLOGICAL RESEARCH, 2019, 147
  • [30] Efficacy and safety of baricitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic DMARDs and/or biological DMARDs: Data from a local registry
    Rosas, Jose
    Senabre-Gallego, Jose Miguel
    Santos-Soler, Gregorio
    Bernal, Jose Antonio
    Bas, Ana Pons
    REUMATOLOGIA CLINICA, 2022, 18 (03): : 188 - 189
12345